JP2014527995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527995A5 JP2014527995A5 JP2014532367A JP2014532367A JP2014527995A5 JP 2014527995 A5 JP2014527995 A5 JP 2014527995A5 JP 2014532367 A JP2014532367 A JP 2014532367A JP 2014532367 A JP2014532367 A JP 2014532367A JP 2014527995 A5 JP2014527995 A5 JP 2014527995A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- aminosulfonyl
- thiazol
- pyridinyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 21
- IVZKZONQVYTCKC-UHFFFAOYSA-N bay 57-1293 Chemical compound N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 IVZKZONQVYTCKC-UHFFFAOYSA-N 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims 2
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims 2
- 229960004150 aciclovir Drugs 0.000 claims 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 2
- 229960000724 cidofovir Drugs 0.000 claims 2
- 229960004396 famciclovir Drugs 0.000 claims 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims 2
- 229960005102 foscarnet Drugs 0.000 claims 2
- 229960002963 ganciclovir Drugs 0.000 claims 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 2
- 229960004716 idoxuridine Drugs 0.000 claims 2
- QPIDAZSAUYNBAC-UHFFFAOYSA-N methanesulfonic acid;n-methyl-n-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide;hydrate Chemical compound O.CS(O)(=O)=O.N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 QPIDAZSAUYNBAC-UHFFFAOYSA-N 0.000 claims 2
- 150000004682 monohydrates Chemical class 0.000 claims 2
- 229960001179 penciclovir Drugs 0.000 claims 2
- 229960003962 trifluridine Drugs 0.000 claims 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims 2
- 229940093257 valacyclovir Drugs 0.000 claims 2
- 229960002149 valganciclovir Drugs 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000005541 medical transmission Effects 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- OIXMUQLVDNPHNS-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O OIXMUQLVDNPHNS-UHFFFAOYSA-N 0.000 claims 1
- PPAJHCGEURRDOG-UHFFFAOYSA-N methanesulfonic acid;n-methyl-n-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide Chemical compound CS(O)(=O)=O.N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 PPAJHCGEURRDOG-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11007803A EP2573085A1 (en) | 2011-09-26 | 2011-09-26 | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| EP11007803.7 | 2011-09-26 | ||
| PCT/EP2012/068958 WO2013045491A1 (en) | 2011-09-26 | 2012-09-26 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527995A JP2014527995A (ja) | 2014-10-23 |
| JP2014527995A5 true JP2014527995A5 (enExample) | 2015-10-29 |
| JP6043356B2 JP6043356B2 (ja) | 2016-12-14 |
Family
ID=46889071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532367A Active JP6043356B2 (ja) | 2011-09-26 | 2012-09-26 | 医薬製剤用の特定粒径分布範囲および比表面積範囲を有するｎ−［５−（アミノスルホニル）−４−メチル−１，３−チアゾール−２−イル］−ｎ−メチル−２−［４−（２−ピリジニル）フェニル］アセトアミドメシレート一水和物 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9119786B2 (enExample) |
| EP (1) | EP2573085A1 (enExample) |
| JP (1) | JP6043356B2 (enExample) |
| KR (1) | KR20140066705A (enExample) |
| CN (1) | CN103842360B (enExample) |
| AU (1) | AU2012314473B2 (enExample) |
| IN (1) | IN2014DN01992A (enExample) |
| MX (1) | MX364094B (enExample) |
| RU (1) | RU2606628C2 (enExample) |
| WO (1) | WO2013045491A1 (enExample) |
| ZA (1) | ZA201401774B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| KR20150119089A (ko) * | 2013-02-12 | 2015-10-23 | 아이쿠리스 게엠베하 운트 코. 카게 | 알츠하이머병 치료 방법에 사용하기 위한 헬리카제-프리마제 억제제 |
| JP2017530132A (ja) * | 2014-09-26 | 2017-10-12 | ミレンド セラピューティクス， インコーポレイテッド | Ｎ−（２，６−ビス（１−メチルエチル）フェニル）−ｎ’−（（１−（４−（ジメチルアミノ）フェニル）シクロペンチル）メチル）尿素塩酸塩の固体薬物形態ならびにこれに関係する組成物、方法、およびキット |
| SI3135275T1 (sl) * | 2015-08-27 | 2020-09-30 | Grindeks, A Joint Stock Company | Farmacevtski pripravek, ki je sposoben vključitve lenalidomida v različnih kristaliničnih modifikacijah |
| RS61905B1 (sr) * | 2016-11-28 | 2021-06-30 | Aicuris Gmbh & Co Kg | Hemihidrat slobodne baze n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida, postupci njegove proizvodnje i upotrebe |
| TWI753972B (zh) | 2016-11-28 | 2022-02-01 | 德商艾庫瑞斯公司 | N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之游離鹼的順丁烯二酸鹽，醫藥調配物、製造方法及其用途 |
| UY37497A (es) | 2016-11-28 | 2018-06-29 | Aicuris Anti Infective Cures Gmbh | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida |
| CN110831577B (zh) | 2017-06-28 | 2023-11-28 | 艾库里斯有限及两合公司 | 包含抗病毒化合物的阴道内施用型装置 |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| CN119816497A (zh) | 2022-08-29 | 2025-04-11 | 组装生物科学股份有限公司 | 普瑞利韦的新的结晶形式 |
| CN119731171A (zh) | 2022-08-29 | 2025-03-28 | 组装生物科学股份有限公司 | 普瑞利韦的新的结晶形式 |
| JP2025530762A (ja) | 2022-08-29 | 2025-09-17 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | ヘルペスウイルス用医薬組成物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
| US6348503B1 (en) | 1996-02-12 | 2002-02-19 | Meryl J. Squires | Method and topical treatment composition for herpesvirus hominis |
| US6355684B1 (en) * | 1990-10-11 | 2002-03-12 | Meryl J. Squires | Antimicrobial treatment for herpes simplex virus and other infectious diseases |
| US9662360B2 (en) | 2008-10-09 | 2017-05-30 | Meritus Corporation | Treatment of herpes, pseudomonas, staph, and hepatitis |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| AU2000259734A1 (en) * | 2000-06-15 | 2001-12-24 | Gerald Kleymann | Method for identifying compounds with anti-herpes activity |
| DE10129714A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10129716A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129717A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10131128A1 (de) * | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| JP2007314516A (ja) | 2006-04-25 | 2007-12-06 | Daiichi Sankyo Co Ltd | ２以上の置換基を有するベンゼン化合物を含有する医薬 |
| JP2009539881A (ja) | 2006-06-09 | 2009-11-19 | アイコス コーポレイション | Ｄｐ−２アンタゴニストとしての置換フェニル酢酸 |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| KR20150119089A (ko) * | 2013-02-12 | 2015-10-23 | 아이쿠리스 게엠베하 운트 코. 카게 | 알츠하이머병 치료 방법에 사용하기 위한 헬리카제-프리마제 억제제 |
| JP2017530132A (ja) | 2014-09-26 | 2017-10-12 | ミレンド セラピューティクス， インコーポレイテッド | Ｎ−（２，６−ビス（１−メチルエチル）フェニル）−ｎ’−（（１−（４−（ジメチルアミノ）フェニル）シクロペンチル）メチル）尿素塩酸塩の固体薬物形態ならびにこれに関係する組成物、方法、およびキット |
| RS61905B1 (sr) | 2016-11-28 | 2021-06-30 | Aicuris Gmbh & Co Kg | Hemihidrat slobodne baze n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida, postupci njegove proizvodnje i upotrebe |
| TWI753972B (zh) | 2016-11-28 | 2022-02-01 | 德商艾庫瑞斯公司 | N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之游離鹼的順丁烯二酸鹽，醫藥調配物、製造方法及其用途 |
| KR102335327B1 (ko) | 2017-04-28 | 2021-12-03 | 현대자동차 주식회사 | 수냉식 이지알 쿨러 |
| CN110831577B (zh) | 2017-06-28 | 2023-11-28 | 艾库里斯有限及两合公司 | 包含抗病毒化合物的阴道内施用型装置 |
-
2011
- 2011-09-26 EP EP11007803A patent/EP2573085A1/en not_active Withdrawn
-
2012
- 2012-09-26 AU AU2012314473A patent/AU2012314473B2/en active Active
- 2012-09-26 MX MX2014003623A patent/MX364094B/es active IP Right Grant
- 2012-09-26 KR KR1020147004027A patent/KR20140066705A/ko not_active Ceased
- 2012-09-26 CN CN201280046748.4A patent/CN103842360B/zh active Active
- 2012-09-26 WO PCT/EP2012/068958 patent/WO2013045491A1/en not_active Ceased
- 2012-09-26 RU RU2014116621A patent/RU2606628C2/ru active
- 2012-09-26 IN IN1992DEN2014 patent/IN2014DN01992A/en unknown
- 2012-09-26 JP JP2014532367A patent/JP6043356B2/ja active Active
-
2013
- 2013-11-01 US US14/069,850 patent/US9119786B2/en active Active
-
2014
- 2014-03-11 ZA ZA2014/01774A patent/ZA201401774B/en unknown
-
2015
- 2015-08-31 US US14/840,763 patent/US9592225B2/en active Active
- 2015-08-31 US US14/840,690 patent/US9889124B2/en active Active
-
2017
- 2017-08-22 US US15/683,127 patent/US10137117B2/en not_active Ceased
-
2020
- 2020-11-25 US US17/104,028 patent/USRE49697E1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527995A5 (enExample) | ||
| RU2014116621A (ru) | Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида, обладающий определенным диапазоном распределения частиц по размерам и удельной площади поверхности, для использования в фармацевтических препаратах | |
| JP2015512931A5 (enExample) | ||
| JP2009512663A5 (enExample) | ||
| US8710079B2 (en) | Quinoline compounds and their use for treating viral infection | |
| JP2017504611A5 (enExample) | ||
| JP2019513804A5 (enExample) | ||
| JP2010528011A5 (enExample) | ||
| JP2012184264A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| JP2013542981A5 (enExample) | ||
| JP2018529770A5 (enExample) | ||
| HRP20151357T1 (hr) | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa | |
| JP2016515128A5 (enExample) | ||
| JP2014012726A5 (enExample) | ||
| JP2011246469A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| JP2012530615A5 (enExample) | ||
| NZ628444A (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| JP2013520167A5 (enExample) | ||
| WO2013132457A3 (en) | Nanocrystalline solid dispersion compositions and process of preparation thereof | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| JP2013542945A5 (enExample) | ||
| JP2017515840A5 (enExample) | ||
| JP2015501777A5 (enExample) |